Apollomics (APLM)
NASDAQ:APLM
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$15.01M
Enterprise Value$13.66M
Total Cash (Recent Filing)$9.77M
Total Debt (Recent Filing)$966.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,103,348
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.86
Price to Sales (P/S)45.62
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue68.98
Enterprise Value/Gross Profit68.98
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology PipelineA clear, clinical-stage oncology focus concentrates R&D resources and expertise, improving trial prioritization and partner visibility. Structural focus increases the chance that successful trial readouts produce lasting value and strategic partnerships over the next 2–6 months.
Relatively Low Financial LeverageLow debt reduces fixed interest obligations and preserves financial flexibility, enabling management to fund near-term clinical programs via equity, partnerships, or limited borrowings. This durability supports operations through multi-month trial cycles.
Lean Operating FootprintA very small headcount implies lower fixed operating costs and a lean cost base, helping extend runway per cash dollar and allowing focused resource allocation to key clinical programs. This structural cost discipline supports sustainability absent big revenue swings.
Bears Say
Persistent Negative Operating And Free Cash FlowsOngoing negative operating and free cash flows erode liquidity and force reliance on dilutive financings or partnership deals to fund trials. Over months this constraint can delay programs, dilute shareholders, and limit strategic optionality if not resolved.
Significant Revenue Decline And VolatilityA dramatic, recent revenue drop reduces internal funding capacity and signals weak commercial or licensing cash-ins. Revenue instability increases dependence on external capital and heightens execution risk for clinical programs over the next 2–6 months.
Ongoing Operating Losses And Weak Profitability MetricsPersistent operating losses and negative margins depress equity returns and have produced negative ROE and equity instability. Structurally, poor profitability limits reinvestment ability and raises the probability of dilutive capital raises absent clinical or partnership wins.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $15.01M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 164 days.
How were Apollomics’s earnings last quarter?
Currently, no data Available
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 1,103,348 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Apollomics
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―